Drugs / KITE-363
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07304154 | Apr 2026 → Jun 2029 expected | multiple sclerosis, myasthenia gravis, polyneuropathy, inflammatory demyelinating, chronic | Kite, A Gilead Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07038447 | Jul 2025 → Sep 2030 expected | idiopathic inflammatory myopathy, lupus nephritis, systemic lupus erythematosus, systemic sclerosis | Kite, A Gilead Company | Enrolling by invitation | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04989803 | Oct 2021 → Feb 2030 expected | B-cell non-Hodgkin lymphoma | Kite, A Gilead Company | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-12-06 | Kite, A Gilead Company | Results Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 kitepharma.com ↗
Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). |
| 2025-12-06 | Gilead Sciences | Results Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 gilead.com ↗
Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). |
| 2025-11-03 | Kite, A Gilead Company | Results Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 kitepharma.com ↗
No delayed neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barré syndrome, and no immune-mediated enterocolitis, have been observed to date. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-06 | Kite, A Gilead Company | Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 kitepharma.com ↗ |
| 2025-12-06 | Gilead Sciences | Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 gilead.com ↗ |
| 2025-11-03 | Kite, A Gilead Company | Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 kitepharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KITE-363 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07304154 ↗ |
| Modality | Cell therapy | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT04989803 ↗ |
| Route | Intravenous | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT04989803 ↗ |
| Target | CD19 | “KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy” NCT07038447 ↗ |